Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 120Mesothelioma 70Solid Tumor 46Solid Tumors 33Retinoblastoma 27Solitary Fibrous Tumor, Pleural 20Sarcoma 17Advanced Solid Tumor 16Advanced Solid Tumors 15Lung Neoplasms 13Small Cell Lung Carcinoma 12Carcinoma, Non-Small-Cell Lung 11Osteosarcoma 9Neuroblastoma 8Ovarian Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumor, Adult 6Colorectal Neoplasms 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Stomach Neoplasms 5Neoplasms 5Melanoma 5Medulloblastoma 5Chondrosarcoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Rare Malignant Solid Neoplasm × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡